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SUMMARY
Introduction of pneumococcal polysaccharide (PPV23) and conjugate vaccine (PCV7)
programmes were expected to change the epidemiology of invasive pneumococcal disease (IPD)
and pneumonia in the UK. We describe the epidemiology of IPD and hospitalization with
pneumonia using high-quality surveillance data over an 8-year period, 2002–2009. Although
PPV23 uptake increased from 49% to 70% and PCV7 uptake reached 98% by 2009, the overall
incidence of IPD increased from 11.8/100 000 to 16.4/100 000 (P=0.13), and the incidence of
hospitalization with pneumonia increased from 143/100 000 to 207/100 000 (P<0.001). Although
a reduction in the proportion of IPD caused by PCV7 serotypes was observed, concurrent
increases in PPV23 and non-vaccine serotype IPD contributed to an increased IPD burden
overall. Marked inequalities in the geographical distribution of disease were observed. Existing
vaccination programmes have, so far, not been suﬃcient to address an increasing burden of
pneumococcal disease in our locality.
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INTRODUCTION
Streptococcus pneumoniae is a leading cause of mor-
bidity and mortality from community-acquired
pneumonia (CAP) worldwide, and can cause invasive
disease, for example, bacteraemia, meningitis, and
septic arthritis [1, 2]. There are currently two pneumo-
coccal vaccines used in the UK, where all vaccine
programmes are publically funded without cost to the
user at the point of care. The pneumococcal poly-
saccharide vaccine (PPV23), which contains antigens
from 23 serotypes of S. pneumoniae, was introduced in
1992 for high-risk groups [those with asplenia or
dysfunction of the spleen, chronic respiratory, heart,
renal or liver disease, diabetes (requiring insulin
or oral hypoglycaemic drugs), immunosuppression,
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individuals with cochlear implants, and individuals
with cerebrospinal ﬂuid (CSF) leaks]. The PPV23
programme was expanded to cover all persons aged
o65 years in April 2005 (phased introduction with
vaccination initially recommended to all those aged
>80 years in August 2003 and then to those aged
>75 years in April 2004). The pneumococcal conju-
gate vaccine (PCV), which previously contained anti-
gens from seven serotypes (PCV7) and since 2010 has
covered 13 serotypes (PCV13), was introduced for
those aged<2 years at a higher risk of pneumococcal
infection in 2002, and was subsequently included in
the routine childhood immunization programme in
September 2006.
There is controversy about the eﬀectiveness of
PPV23 in older adults [3–6]. Only one small random-
ized controlled trial has demonstrated protective
eﬃcacy of PPV23 against pneumonia [7]. Evidence
from observational studies has suggested that PPV23
is eﬀective in reducing the incidence of invasive
pneumococcal disease (IPD) (protective eﬃcacy of
about 45%) [8–10], but not pneumonia or mortality,
although the validity of this evidence has been ques-
tioned [6]. There is no controversy regarding PCV7,
which has been demonstrated to be eﬀective in re-
ducing vaccine serotype pneumococcal disease in
children in the USA [11]. Furthermore, a reduction in
IPD in all age groups in the USA has been attributed
to herd immunity following the introduction of PCV7
into routine childhood immunization programmes
[12, 13]. PCV7 has subsequently been introduced
across Europe, where early studies have demon-
strated a reduction in IPD rates in children and adults
[14–17]. However, vaccine serotype coverage by
PCV7 in the USA (>80%) was greater than that in
Europe (60–70%) at the time of its introduction and
a greater increase in non-PCV serotype disease has
subsequently been recorded in European countries
[14–18]. Because it is not guaranteed that the eﬀect of
vaccination will be the same in all populations, even
within the same country, high-quality surveillance
data is essential at both local and national levels to
monitor the epidemiology of pneumococcal disease.
The population of Hull (y264 500) has a much
higher prevalence of comorbid illness and unhealthy
behaviour, such as smoking, and a shorter life ex-
pectancy than the average for England, and is known
to be more deprived with over 50% of the population
living within the most deprived national quintile [19,
20]. The population of the East Riding of Yorkshire
(ERoY) (y346 000), in comparison, is relatively
aﬄuent with a longer life expectancy and better health
indicators than averages for England [19, 21]. In both
Hull and ERoY, PPV23 has been recommended for
all those aged o65 years since 2002, anticipating
the national recommendation by 3 years. The local
Health Protection Unit (HPU), in contrast to many
other areas of the UK, has been actively collecting
patient-level surveillance data from primary-care
General Practitioners (GPs) on PPV23 vaccination
uptake since its introduction.
The purpose of this study was to describe the epi-
demiology of IPD and pneumonia in Hull and ERoY
over an 8-year period during which PPV23 and PCV7
vaccination programmes were introduced. Our pri-
mary hypothesis was that a reduction in the incidence
of IPD and pneumonia in the target groups for vac-
cination would have occurred during the study period.
Secondary hypotheses were that : a reduction in
the incidence of IPD and pneumonia would have
occurred in other age groups as a result of herd im-
munity, particularly in relation to PCV7 introduc-
tion; vaccine serotype IPD would have decreased;
and that there would be an association between the
incidence of IPD and the degree of deprivation within
a locality.
METHODS
Surveillance and data collection
The computer databases of the microbiology labora-
tories of Hull and East Yorkshire Hospitals (HEY)
NHS Trust and of hospitals from three NHS Trusts
bordering Hull and ERoY (comprising eight hospitals
in total that routinely receive admissions of in-
dividuals resident in Hull and ERoY) (Supplementary
Table S1, available online), were retrospectively in-
terrogated in order to identify pneumococcal isolates
cultured from samples retrieved from normally sterile
body sites (blood, CSF, and joint, pleural or ascitic
ﬂuids), from 1 January 2002 to 31 December 2009.
Information from all four Trust microbiology
laboratories was obtained for the complete time
period 2002–2009 with the exception of one, North
Lincolnshire and Goole (NLG) Hospitals NHS
Foundation Trust, where data for the years 2002 and
2003 were unavailable. The main NLG hospital con-
cerned lies outside the boundaries of Hull and ERoY
and, in relation to this study, serves a small catchment
area of just one postcode district (Goole, DN14). In
order to account for the missing data, the population
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numbers for that postcode for 2002 and 2003 were
subtracted from all the population denominators used
in the calculation of incidence rates. In addition,
positive pneumococcal PCR results for residents of
Hull and ERoY were retrospectively identiﬁed from
the reports received from supra-regional testing lab-
oratories held by the HPU. Individuals were classiﬁed
as a case of IPD if S. pneumoniae was cultured from
a normally sterile body site and/or pneumococcal
DNA was detected by PCR of blood and/or CSF.
Demographic details of cases (including postcode
district) were obtained from the Trust microbiology
and/or pathology databases. Only individuals resi-
dent in Hull and ERoY, deﬁned by the postcode of
residence lying within the recognized geographical
boundaries of the Hull and ERoY Primary Care
Trusts (PCTs), were included. Information concern-
ing the origin of pneumococcal isolates cultured from
samples received within the ﬁrst 24 h of admission,
and the serotype of isolates (tested by the Respiratory
and Systemic Infection Laboratory, Colindale,
London, UK) were recorded. In order to avoid the
same patient episode being included more than once,
further subsequent isolates from specimens taken
within 30 days of the index isolate(s) were excluded.
In order to make an assessment of the contribution
of changing laboratory and/or clinical (sampling)
practice in relation to the diagnosis of IPD, infor-
mation on the number of blood cultures submitted to
microbiology laboratories and changes in laboratory
practices were obtained. Numbers of hospital ad-
missions were also obtained from hospital trust in-
formation services in order to calculate the incidence
of blood culture sampling.
For the years 2005/2006 to 2009/2010, information
on population vaccination uptake was derived from
the results of PPV uptake surveys, performed and
published by the Health Protection Agency (HPA),
concerning the populations covered by Hull and
ERoY PCTs, using the same geographical boundaries
as deﬁned above [22]. For the years 2001/2002 to
2004/2005, in which HPA surveys were not per-
formed, vaccination uptake was calculated using data
from the HPU PPV vaccination surveillance data-
base. PPV vaccination status of IPD cases aged o65
years was ascertained by matching the identity of IPD
cases with individuals in the HPU vaccination sur-
veillance database. Both the national HPA and the
local HPU datasets provided population numbers
vaccinated (and not vaccinated) by year, which were
used as denominator populations (person-years) in
the calculation of PPV23 eﬀectiveness as detailed be-
low. Date of death (if applicable) of IPD cases was
recorded from the National Health Service Spine
Summary Care database.
Hull and ERoY PCTs provided data on the number
of hospital admissions of residents of Hull and ERoY
with a diagnosis of pneumonia (2002–2009), which
was established by searching the Healthcare Pur-
chaser System database (containing information from
the Secondary Uses Service, the national central
repository for healthcare data) for the following
ICD-10 codes in the primary diagnostic ﬁeld: J18.0
bronchopneumonia, J18.9 pneumonia (unspeciﬁed),
J13X pneumococcal pneumonia, J18.1 lobar pneu-
monia and J15X bacterial pneumonia not elsewhere
classiﬁed; residence in Hull and ERoY was deﬁned by
residential postcode and/or GP registration lying
within the PCT geographical boundaries outlined
above. As an unrelated ‘observational control ’ (for
data validation purposes), the numbers of admissions
of residents with a primary diagnosis of fractured
neck of femur over the same time period were estab-
lished by the same method for the following ICD-10
codes: S720 fracture of neck of femur, S721 per-
trochanteric fracture, S722 subtrochanteric fracture.
To replicate the method used to identify IPD cases
and compare the incidence of IPD with another
community-acquired infectious disease for which a
vaccine is not available, the number of conﬁrmed in-
vasive group B meningococcal infections in residents
of Hull and ERoY from 2002 to 2009, whose samples
were obtained from the same hospitals, was deter-
mined from records held at the HPU. [Invasive group
B meningococcal infections (diagnosed when group B
meningococcus is cultured or diagnosed by PCR from
a sample retrieved from a sterile body site, and there
are clinical signs and symptoms indicative of infec-
tion), are subject to statutory notiﬁcation to HPUs in
the UK.]
Statistical analyses and hypotheses testing
Descriptive statistics are presented as numbers and
percentages. Crude incidence rates were calculated
using mid-year population estimates for Hull and
ERoY published by the Oﬃce for National Statistics
(ONS) [19]. Age- and sex-speciﬁc incidence rates were
calculated. The 95% conﬁdence interval (CI) formula
used is based on the Poisson distribution.
Poisson regression was undertaken to compare
the incidence rates annually ; and was also undertaken
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to compare incidence rates within age groups and
by gender in order to detect changes in incidence
(as used in a previous UK IPD study) [10]. x2 tests
were used to compare the proportions of IPD cases
caused by vaccine and non-vaccine serotypes. PPV23
eﬀectiveness was estimated using the screening
method:
100r
IR in unvaccinated groupxIR in vaccinated group
IR in unvaccinated group
,
where IR=incidence rate [23].
In order to make comparisons, incidence density
rates were calculated separately for the populations
of Hull and ERoY, for the entire study period using
ONS population estimates as the denominator.
Incidence density rates were also calculated by post-
code district separately for Hull and ERoY for the
entire study period using resident population
estimates (residence deﬁned by postcode, as above)
supplied by Hull and ERoY PCTs from the primary
care, general practice (GP), patient registration ﬁle
as the denominator. Incidence density rates were di-
rectly age-standardized to the European Standard
Population and 95% CIs were calculated according
to the preferred method of the Association of
Public Health Observatories (APHO) (utilizing pre-
formulated APHO spreadsheet tools), using Byar’s
approximation (for numerators above 389) or com-
puted from the Poisson distribution (for numerators
f389) [24]. To compare incidence rates between Hull
and ERoY and between postcode districts, Poisson
regression was undertaken. A Mann–Whitney test
was undertaken to compare age at death between Hull
and ERoY and x2 tests were used to compare case-
fatality. A population-weighted mean deprivation
score [index of multiple deprivation (IMD) 2007] was
calculated for each postcode district and was supplied
by the PCTs [25]. Spearman’s rank correlations were
calculated to explore the relationship between depri-
vation and incidence of IPD which was assumed to be
nonlinear in nature.
To explore the relationship between numbers
of blood cultures submitted and IPD incidence,
Spearman’s rank correlations were calculated. Poisson
regression was undertaken to compare blood culture-
sampling incidence rates between annual data in order
to assess any potential changes in sampling practices.
In the same manner as for IPD, Poisson regression
was undertaken to compare incidence rates for frac-
tured neck of femur and for invasive group B men-
ingococcal disease.
A P value of <0.05 was considered to indicate
statistical signiﬁcance. No adjustments were made for
multiple testing in keeping with the recommendations
of Perneger, who stated that ‘simply describing what
tests of signiﬁcance have been performed, and why, is
generally the best way of dealing with multiple com-
parison’ [26]. All data were recorded and analysed
using PASW Statistics v. 18 (IBM, USA). Data and
information sources are summarized in Supplemen-
tary Table S2 (online).
Advice was sought from the National Research
Ethics Service (NRES) prior to study commence-
ment; this work was classiﬁed as surveillance and did
not require formal review by an ethics committee.
RESULTS
Study sample
Of the 653 patients with IPD (730 positive micro-
biological samples), 350 (53.6%) were male ; their
median age was 68 years (55.7% agedo65 years, age
range 0–102 years). The age and gender distribution
of IPD cases is shown in Figure 1. The ratio of male
to female IPD cases was 1.16. There were 668
(91.5%) pneumococcal isolates cultured from blood,
17 (2.3%) from CSF, 17 (2.3%) from pleural ﬂuid,
eight (1.1%) from synovial ﬂuid and three (0.4%)
from ascitic ﬂuid; PCR results indicative of pneumo-
coccal infection were retrieved for 16 samples : 10
(1.4%) from CSF and six (0.8%) from blood.
In total, 561 (85.9%) of the 653 individuals had
presented to the three hospitals of HEY Hospitals
NHS Trust, 49 (7.5%) to the two hospitals of
Scarborough and North East Yorkshire (NEY) NHS
Trust, 27 (4.1%) to York Teaching Hospital (YTH),
and 16 (2.5%) to the two hospitals of North
Lincolnshire and Goole (NLG) Hospitals NHS
Foundation Trust.
Incidence of IPD
The number of conﬁrmed cases of IPD increased from
65 in 2002 to 99 in 2009, corresponding to a rise
in overall incidence of IPD from 11.8 (95% CI
9.14–15.1) to 16.4 (95% CI 12.4–18.9) per 100 000
(Table 1) (Poisson regression, P=0.13). The incidence
of IPD by age range is shown in Figure 2. The inci-
dence of IPD in those aged o65 years (the target
group for PPV23) increased from 40.0 (95% CI
28.3–54.9) to 45.5 (95% CI 33.5–60.3) per 100 000
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from 2002 to 2009 (Poisson regression, P=0.69).
In contrast, the incidence of IPD in those aged 15–64
years signiﬁcantly increased from 5.0 (95% CI
3.0–8.0) to 11.2 (95% CI 8.2–15.0) per 100 000
(Poisson regression, P=0.02) over the study period.
There was no signiﬁcant change in the incidence of
IPD in those aged 5–14 years (Poisson regression,
P=0.91) ; nor in those aged <5 years (includes the
target group for PCV7) over the study period (Poisson
regression, P=0.54) or post-PCV7 introduction
(Poisson regression, P=0.34).
The incidence rates for IPD in Hull and ERoY are
compared to published national rates and those re-
cently published for the population of Oxfordshire,
England in Table 1.
Vaccination uptake
Over the same period, vaccination uptake for PPV in
the o65 years age group increased from 49% (95%
CI 48.6–49.3) to 70% (95% CI 69.5–70.0) and uptake
of PCV7 in those aged <2 years had reached 98%
(95% CI 95.3–100.1) by 2009 (Fig. 3).
Blood culture sampling, laboratory methods and
antimicrobial susceptibilities
The number of blood cultures received by HEY
Hospitals NHS Trust (where 85.9% of the IPD cases
were diagnosed) each year and the incidence of IPD is
shown in Figure 4. There was no signiﬁcant corre-
lation between the numbers of blood cultures sub-
mitted and the incidence of IPD (Spearman’s rank
correlations, rs=0.48, P=0.23). The incidence of
blood culture sampling in those admitted to HEY
hospitals actually decreased over the study period
from 103 (95% CI 101–104) to 91 (95% CI 89–92)
per 1000 admissions (Poisson regression, P<0.001).
In addition there were no reported major changes
in laboratory methodology in relation to the diagnosis
of IPD or pneumonia over the study period. Anti-
microbial susceptibilities were available for all 714
culture isolates. Resistance to penicillin occurred in
eight (1.1%) isolates and resistance to macrolides
in 63 (8.8%); resistance was stable over the study
period.
Mortality following IPD
A total of 141 (21.6%) IPD cases had died within
30 days of the invasive pneumococcal isolate. This
included ﬁve deaths in those aged<5 years (10.2% of
IPD cases aged <5 years), zero in those aged 5–14
years, 30 in those aged 15–64 years (13.3% of cases
aged 15–64 years), and 106 in those aged o65 years
(29.1% of cases aged o65 years). Within 1 year 240
(36.8%) cases had died, of which 50 (20.8%) were
aged 15–64 years and 185 (77.1%) were aged o65
years (there were no additional deaths between
30 days and 1 year in those aged<5 years). The case-
fatality rate within 30 days was non-signiﬁcantly
higher in men (24.3% vs. 18.5%) (x2, P=0.07).
Pneumococcal serotypes
A serotype result was available for 478 (75%) of the
639 culture-positive IPD cases. The number and pro-
portion of IPD cases for which a serotype result was
available increased over time (Table 2). Overall, 34
distinct pneumococcal serotypes were detected. Of the
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isolates 426 (89%) were PPV23 serotypes and 157
(33%) were PCV7 serotypes. The proportion of IPD
cases caused by serotypes covered by both PPV23 and
PCV7 (the PCV7 serotypes) did not change signiﬁ-
cantly prior to PCV7 introduction (range 39–61%,
x2, P=0.34) ; however, post-PCV7 introduction fell
sharply (from a baseline of 52% to 12%, x2,
P<0.001), and the proportion of IPD cases caused
by PPV23 serotypes increased post-PCV7 (from 39%
to 69%, x2, P<0.05). The proportion of IPD cases
caused by non-vaccine serotypes appeared to increase
post-PCV7 introduction (from 9% to 19%), although
this was non-signiﬁcant (x2, P=0.26) (Table 2).
Vaccine eﬀectiveness
Of the 364 IPD cases agedo65 years, 212 (58%) were
known to have received PPV23 prior to their episode
of IPD. The median time from vaccination with
PPV23 to IPD episode was 4 years and 2 months
(range 2 months to 13 years). Serotype information
was available for 164 (77%) of the previously vacci-
nated cases ; 138 (84%) of these had infections caused
by PPV23 serotypes and were therefore considered
‘vaccine failures ’. Overall incidence in theo65 years
age group known to have previously received PPV23
was 41.5 (95% CI 36.1–47.5) per 100 000 person-years
Table 1. Number of cases, incidence and mortality of invasive pneumococcal disease per 100 000 by year
Year
Number of
cases
Incidence,
Hull and
ERoY
30-day
mortality
Incidence
Oxfordshire,
England* [17]
Incidence
England
and Wales* [27]
2002 65 11.8 14 (22%) 8.9 9.1
2003 60 10.9 8 (13%) 10.3 10.1
2004 74 12.6 12 (16%) 8.8 10.8
2005 90 15.3 20 (22%) 7.9 11.8
2006 81 13.8 24 (30%) 8.4 11.9
2007 91 15.4 19 (21%) 8.7 n.a.
2008 93 15.5 27 (29%) 8.1 n.a.
2009 99 16.4 17 (17%) 7.1 n.a.
ERoY, East Riding of Yorkshire ; n.a., not available.
* Rates were measured July–June, therefore 2002 refers to rates of 2001/2002, 2003 to 2002/2003 and so on; rates for
2007–2009 for England and Wales were not available.
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compared to 48.8 (95% CI 41.4–57.2) per 100 000
person-years in those without a record of vaccination
prior to IPD; PPV23 eﬀectiveness was thus estimated
to be 15% (95% CIx4.6 to 31).
Incidence of hospitalization with pneumonia
The numbers and incidence of hospitalizations with
pneumonia increased every year of the study period
from 833 cases (143/100 000, 95% CI 133–153) in
2002 to 1250 (207/100 000, 95% CI 195.5–218.6)
in 2009 (Poisson regression, P<0.001), an increase in
incidence of 45%. The incidence of pneumonia by age
range is shown in Figure 5. Incidence increased sig-
niﬁcantly in adults, with an increase of 44% in those
aged o65 years [from 543 (95% CI 498–590) to 781
(95% CI 729, 836) per 100 000 (Poisson regression,
P<0.001)] and 72% in those aged 15–64 years [from
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48.8 (95% CI 42.1–56.4) to 84.1 (95% CI 75.4–93.6)
per 100 000 (Poisson regression, P<0.001)] from 2002
to 2009. Incidence in those aged <5 years did not
change signiﬁcantly between 2002 and 2005, but de-
creased in 2006–2009, from 309 (95% CI 250–378) to
167 (95% CI 126–218) (Poisson regression, P<0.001)
post-introduction of PCV7. Incidence in those aged
5–14 years did not change signiﬁcantly over the study
period (Poisson regression, P=0.90).
Incidence of invasive group B meningococcal infection
and of hospitalization with fractured neck of femur
(‘observational controls ’)
Reports of 98 invasive group B meningococcal infec-
tions were identiﬁed; the incidence of these infections
was highly variable year to year and did not change
signiﬁcantly overall from 2002 to 2009 (Poisson re-
gression, P=0.78) (Fig. 6). There were 5035 hospital
Table 2. Cases of invasive pneumococcal disease by pneumococcal serotype
Year
No. (%) of
culture- positive
cases with
serotype result
Serotypes
covered by
PPV and PCV*
(PCV7 serotypes)
Serotypes
covered by
PPV but
not PCV#
Serotypes not
covered by PPV
or PCV
(non-vaccine serotypes)
2002 18 (27.7%) 11 (61.1%) 6 (33.3%) 1 (5.6%)
2003 38 (64.4%) 15 (39.5%) 20 (52.6%) 3 (7.9%)
2004 50 (67.6%) 21 (42.0%) 27 (54.0%) 2 (4.0%)
2005 66 (74.2%) 34 (51.5%) 26 (39.4%) 6 (9.1%)
2006 68 (85.0%) 26 (38.2%) 36 (52.9%) 6 (8.8%)
2007 76 (88.4%) 24 (31.6%) 42 (55.3%) 10 (13.2%)
2008 81 (89.0%) 16 (19.8%) 57 (70.4%) 8 (9.9%)
2009 81 (85.3%) 10 (12.3%) 56 (69.1%) 15 (18.5%)
PPV, Pneumococcal polysaccharide vaccine ; PCV, pneumococcal conjugate vaccine.
* Serotypes : 4, 6b, 9V, 14, 18c, 19f, 23f.
# Serotypes : 1, 2, 3, 5, 7f, 8, 9N, 10a, 11a, 12f, 15b, 17f, 19a, 20, 22f, 33f.
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admissions with a primary diagnosis of fracture neck
of femur over the study period and similarly there was
no signiﬁcant change in incidence (Poisson regression,
P=0.22) (Fig. 6).
Geographical distribution of disease, vaccination
uptake and deprivation indices
Over the study period, the overall age-standardized
incidence of IPD in Hull was 14.3 (95% CI 12.8–16.0)
per 100 000 person-years and was considerably higher
than that in ERoY, 8.8 (95% CI 7.7–9.9) per 100 000
person-years. The incidence of IPD was signiﬁcantly
higher in Hull in the o65 years (Poisson regression,
P<0.001) and the 15–64 years (Poisson regression,
P<0.001) age groups, but not in children aged <14
years (Table 3). Similarly, the overall age-standardized
incidence of hospitalization with pneumonia was
higher in Hull (148.3, 95% CI 143–153 per 100000
person-years) compared to ERoY (111.2, 95% CI
107–115 per 100000 person-years) over the study
period. The incidence of pneumonia was signiﬁcantly
higher in Hull for all age groups except those aged<5
years (Table 3).
There was no signiﬁcant diﬀerence in mean PPV23
uptake between Hull and ERoY over the study
period [62.7% (95% CI 62.6–62.9) and 63.3% (95%
CI 63.2%, 63.5%), respectively] (x2, P=0.07). Mean
uptake of PCV7 was marginally higher in ERoY from
2006 to 2009 [74.4% (95% CI 72.9–76.0) compared
to 70.8% (95% CI 69.4%, 72.3%)] (x2, P=0.01),
although it exceeded 94% in both areas by 2008.
A higher incidence of IPD was noted in the most
deprived Hull postcode district and incidence of IPD
was signiﬁcantly related to the postcode IMD score
(Spearman’s rank correlation, R2=0.62, P=0.04)
(Fig. 7). The same pattern was not noted in ERoY
(data not shown), where there were less cases overall
and a larger number of postcode districts.
There was no signiﬁcant diﬀerence in case fatality
within 30 days for IPD between Hull and ERoY [20%
vs. 23%, respectively (x2, P=0.26)], nor median age
at death (which appeared lower in Hull at 78 years
compared to 80.5 years in ERoY), (Mann–Whitney,
P=0.40).
DISCUSSION
Enhanced surveillance of infection and vaccine up-
take from 2002 has shown that despite increasing
uptake of both vaccines, and contrary to our primary
hypothesis, the overall incidence of IPD and pneu-
monia has increased. Importantly, the incidence rates
for IPD presented are likely to be an underestimate of
the true rates : many individuals will not present to
hospitals (particularly the very elderly) ; diagnosis of
IPD is dependent on appropriate samples being sent
at the appropriate time (ideally blood cultures prior to
antimicrobial therapy) ; and some residents of Hull
and ERoY may have presented elsewhere for diag-
nosis and treatment. Whereas other UK studies have
explained an observed increase in IPD incidence as an
artefact of increased sampling [27, 28], our ﬁndings do
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Fig. 6. Incidence of invasive group B meningococcal infection and of hospitalization with fractured neck of femur.
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not support this as the number of blood cultures per-
formed remained relatively stable during the study
period (and the incidence of blood culture sampling
appeared to decrease). The dramatic increase in
the incidence of hospitalization for pneumonia, in
keeping with a recent large epidemiological study
in England and Wales, also suggests that the burden
of pneumococcal disease is increasing in this
locality [29].
A reduction in IPD was not demonstrated in the
main target group for PPV23 or overall. The protective
eﬀect of PPV23 at the population level was found to
be low (and may be overestimated due to under-
reporting of PPV23 vaccination status), and is con-
sistent with the recent assessment by the Joint
Committee on Vaccination and Immunization (JCVI)
UK, that the eﬀectiveness of PPV23 is poor in those
agedo65 years [30]. At the patient level, many ‘vac-
cine failures ’ were identiﬁed. However, the increasing
incidence of IPD may be unrelated to vaccination; for
example, risk factors for IPD may have increased in
adults during the study period. In contrast, we found
Table 3. Incidence density of invasive pneumococcal disease (IPD) and
pneumonia by age in Hull and East Riding of Yorkshire (ERoY), 2002–2009
Age range (years) Hull ERoY
Incidence density of IPD per 100 00 person-years (95% CI)
o65 60.6 (52.2–70.1) 34.0 (29.0–39.6)
15–64 9.1 (7.6–10.9) 5.4 (4.3–6.6)
5–14 3.1 (1.3–6.1) 2.1 (0.8–4.5)
<5 16.3 (10.1–25.0) 21.2 (13.9–31.1)
Incidence density of pneumonia per 100 000 person-years (95% CI)
o65 737 (707–769) 585 (564–606)
15–64 72.3 (67.9–76.9) 56.0 (52.5–59.7)
5–14 60.1 (51.0–71.3) 37.9 (31.2–45.6)
<5 248 (222–277) 207 (183–234)
CI, Conﬁdence interval.
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a signiﬁcant reduction in the incidence of pneumonia
in children aged <5 years following the introduction
of PCV7. While the reduction in the incidence of IPD
in children was not statistically signiﬁcant, we ac-
knowledge that the number of IPD cases in children
was small and the study may therefore have been
performed in too small a population area to detect the
anticipated target population eﬀects of PCV7 seen in
other studies [11–13] [the population aged <5 years
was 32 900 (5.4% of the total population) in 2009]
[19]. However, there was no evidence of herd im-
munity in the larger older cohort during the post-PCV
(post-2006) period. Whether this is due to a delayed
beneﬁcial eﬀect yet to be detected, the relatively small
size of our study compared to some reports, natural
ﬂuctuation of disease incidence, or another reason is
unclear.
The incidence rates of IPD in Hull and ERoY are
higher than those reported nationally and are con-
siderably higher than those in Oxfordshire. National
surveillance requires voluntary reporting of clinically
signiﬁcant isolates by individual microbiology lab-
oratories whereas in this study, information on rel-
evant isolates was actively sought. Therefore, the
higher incidence rates for Hull and ERoY may reﬂect
the more inclusive methodology. However, this does
not explain the large diﬀerence in rates between Hull
and ERoY and Oxfordshire, where enhanced surveil-
lance was also performed, and suggests a genuinely
higher burden of IPD in our locality compared to
more aﬄuent and healthier areas of the UK. It is also
notable that rates of IPD are falling in Oxfordshire.
Together with the observed marked diﬀerences in the
incidence of both IPD and hospitalization for pneu-
monia between Hull and ERoY, this study highlights
the likely presence of important health inequalities
within the population of the UK. Interestingly, HEY
Hospitals NHS trust was recently identiﬁed by the
Dr Foster group as having a higher mortality rate
compared to the average acute UK hospital and it is
suspected that this, at least in part, is explained by the
recognized high level of comorbidity and risk-taking
behaviour in the local population [31]. The higher in-
cidence of IPD in the most deprived Hull postcode
district, the apparent relationship between the inci-
dence of IPD and postcode IMD score within Hull
postcode districts, and the diﬀerences in the in-
cidences of IPD and pneumonia between Hull and the
more aﬄuent ERoY, also suggests that social depri-
vation is an important contributor to IPD, in keeping
with a previous study of children [32]. Deprivation
covers a broad range of issues and refers to unmet
needs resulting from a lack of resources of all kinds,
not just ﬁnancial [25]. The IMD score reﬂects the
measurement of seven distinct domains of deprivation
(diﬀerentially weighted and combined) which include:
income deprivation, employment deprivation, health
deprivation and disability, education skills and train-
ing deprivation, barriers to housing and services,
living environment deprivation, and crime [25]. In
every domain the population of Hull is considered
more deprived than the average for England, and even
within Hull there are also marked inequalities [20, 25].
It is conceivable that deprivation aﬀecting each of the
seven domains might contribute to increased pneumo-
coccal carriage and disease (e.g. it can be speculated
that overcrowded living conditions might lead to
increased transmission and carriage of pneumo-
coccus; and poverty, disability and low educational
level might contribute to delayed presentation of in-
fection and increased likelihood of invasive disease).
However, further research (at the individual level) is
indicated to conﬁrm that such a relationship exists
and to identify the important underlying social
determinants.
The increased burden of pneumococcal disease ob-
served in this study is not explained easily by changes
in population demographics ; although the numbers
of elderly did increase, the growth in the population
aged o65 years (4.6%) was modest over the 8-year
period and similar to the increase (3.5%) in the gen-
eral population. The proportion of the population
aged>80 years was unchanged (4.3% in 2002, 4.6%
in 2009) [19]. Although ERoY has an older popu-
lation compared to Hull and England, the population
of Hull has a lower proportion of elderly, thus the
combined population structure of Hull and ERoY is
similar to that of England [19]. The increases in the
incidence of IPD and pneumonia overall were largely
driven by increases in the adult age groups. The sig-
niﬁcant increase in both IPD and pneumonia in the
15–64 years age group could be explained by an in-
creasing prevalence of risk factors for pneumococcal
disease known to be at a high level in the young adult
population of Hull, such as intravenous drug use,
high alcohol intake, and smoking [20, 25], although
further research is required to conﬁrm this ; such fac-
tors should be important targets for future local
health promotion and research. The increase is not
explained by antibiotic resistance. We were not able
to assess if the prevalence of pneumococcal carriage
in the population also increased. There were no major
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changes in laboratory equipment or blood culture
methodology and, while PCR was used more fre-
quently in later years, the number of cases diagnosed
by this method was low (14 cases, 2%) spread over
the study period (1/59 cases in 2003 vs. 4/95 cases in
2009). Uptake of both PPV23 and PCV7 was higher
in Hull and ERoY compared to the averages for
England [22, 33], and although there was marginally
higher uptake of PCV7 in ERoY compared to Hull,
PCV7 uptake in both areas was high following the
ﬁrst full year of vaccine implementation; PPV23 up-
take was similar in both areas. Thus our observations
cannot be attributed to low vaccine coverage and the
marked diﬀerences between Hull and ERoY are un-
likely to be explained by diﬀerential vaccine uptake.
The reduction in PCV7 serotypes noted after 2006
is consistent with the observations of other studies
and supports the eﬀectiveness of this vaccine in re-
ducing vaccine serotype disease. However, although
an increase in non-PCV7 serotypes after 2006 was to
be expected and in keeping with other studies, the
observed overall increase in the incidence of IPD was
surprising and in contrast to other settings where IPD
rates have been falling post-PCV7 [14–17]. It is
therefore conceivable that a change in the sero-
epidemiology of IPD in our locality, in the period
following PCV7 implementation, has contributed to
an increased overall burden of disease; this appears to
have mostly been due to an increase in non-PCV7,
PPV23 serotypes. A recent large cohort study showed
that some pneumococcal serotypes result in higher
mortality (and presumably therefore more severe,
non-fatal illness) compared to others [34]. Those sero-
types covered by PCV7 are associated with relatively
lower 30-day mortality compared to many non-PCV,
PPV serotypes and non-vaccine serotypes [34]. One
consequence of PCV7 introduction in our locality,
therefore, may have been replacement of PCV7 sero-
types with serotypes more likely to cause severe dis-
ease, although there was no clear evidence of a
signiﬁcant increase in mortality, which was 19% in
the 2002–2005 period compared to 24% in the
2006–2009 period (x2, P=0.20). Diﬀerences in the
predisposition of serotypes to colonize and invade
the human respiratory tract might have also con-
tributed to the overall increase in IPD incidence [35].
The notable increase in mortality (from 22% to 37%)
between 30 days and 1 year after the diagnosis of IPD
entirely occurred in adults (>16 years), especially
those aged o65 years, and suggests that IPD is a
marker of poor 1-year survival. This is likely to be due
to comorbidity, but other explanations, such as the
triggering of an inﬂammatory response resulting in
cardiovascular disease should be investigated.
Our results suggest that the current approach to
pneumococcal vaccination in our locality should be
reviewed. Possible alternative strategies include a
switch to the use of conjugate vaccines in those aged
o65 years (and high-risk patients of any age) [36],
and the development and use of conjugate vaccines
that cover a higher proportion of circulating sero-
types. Studies are currently being performed to assess
the eﬀectiveness of conjugate compared to poly-
saccharide vaccines in older age groups [37], but it
remains unclear as to whether this will be a more cost-
eﬀective strategy than PPV23. The UK has recently
switched to PCV13 for the vaccination of those aged
<2 years and it will be interesting to observe the im-
pact of this in our locality on IPD and pneumonia
both within this age group and in the overall popu-
lation. The results also highlight the importance of
tackling the likely underlying public health determi-
nants of IPD and pneumonia.
We acknowledge that this study has a number of
limitations. The observational design means that the
observed trends cannot be deﬁnitively attributed to
vaccine eﬀectiveness and could be due to natural
ﬂuctuation. It is, however, interesting to note that the
incidence of invasive meningococcal group B infec-
tions did not increase over the study period. The es-
timate of vaccination uptake was based on data
from primary-care practitioners both at a local and
national level. In contrast to other areas in England, a
ﬁnancial incentive is oﬀered in Hull and ERoY by the
HPU for information on PPV23 uptake. The vacci-
nation surveillance database is updated continuously,
with active measures taken annually to identify and
contact non-responding GP practices. Nevertheless,
PPV23 uptake is likely to be underestimated.
There are also limitations to assessing deprivation by
postcode districts, which may contain both areas of
deprivation and comparative aﬄuence. Use of the
IMD score, which is calculated relative to populations
in other postcode districts within the same region,
presents some challenges for interpretation when the
whole region is relatively deprived (as in Hull). In
addition, there are recognized limitations in using
population estimates for the postcode districts derived
from primary care (GP) registrations (PCTs utilize
this data in the absence of ONS population esti-
mates at this geographical level) which tend to over-
estimate population size compared to ONS estimates
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[38] ; incidence density rates of IPD in the postcode
districts might be therefore be underestimated, and
if there was diﬀerential registration between popu-
lations of diﬀerent postcode districts consistently over
the 8-year study period then the association between
deprivation and IPD by postcode district, might be
either over- or under-estimated. We tried to account
for diﬀerences in age distribution within postcode
districts by using directly age-standardized data. The
identiﬁcation of those hospitalized with pneumonia
relied on ICD-10 based case-coding performed after
hospital discharge. While a change in coding practice
and/or clinical practice (e.g. lower threshold for hos-
pital admission) may have occurred over the study
period, this is unlikely to have resulted in the magni-
tude of the observed increases in pneumonia inci-
dence. Indeed the relatively constant incidence of
the observation control, i.e. hospitalization with
fractured neck of femur, would suggest that there was
not a systematic change in coding practice or other
gross bias in data collection over the study period and
thus provides supportive evidence of a true increase
in pneumonia incidence. There are many causes o
pneumonia and the increase cannot be solely attribu-
ted to an increase in the incidence of S. pneumoniae
infection, although S. pneumoniae is well recognized
to be the commonest cause of CAP worldwide. We
included only patients given a primary (ﬁrst position)
diagnostic code for pneumonia in order to increase
the likelihood of identifying true cases of CAP.
Finally, the proportion of isolates sent to the refer-
ence laboratory for typing was particularly low in the
ﬁrst year (2002), but was higher thereafter (between
64% and 89%); this could have aﬀected our results as
it is possible, for example, that isolates from patients
with more severe pneumococcal infection are more
likely to be sent for serotyping. Despite the identiﬁed
limitations, this study provides valuable information
on the epidemiology of IPD and pneumonia and the
early eﬀects of vaccination in a relatively deprived
UK population and suggests that the impact of vac-
cination cannot always be assumed to be consistent
across populations.
In conclusion, the burden of IPD and pneumonia
increased in Hull and ERoY from 2002 to 2009 de-
spite improved uptake of both PPV23 and PCV7 vac-
cines. The underlying determinants of this trend are
unclear, and may be independent of vaccine intro-
duction, but should be explored. Existing vaccination
programmes alone might not be suﬃcient to reverse
the burden of pneumococcal disease, particularly in
areas with a high prevalence of comorbid illness and
social deprivation, and our ﬁndings are consistent with
the JCVI assessment that PPV23 eﬀectiveness is poor
in those aged o65 years [28]. Further investigation
of the social determinants of pneumococcal disease
is required. Surveillance of pneumococcal serotype
distribution and monitoring of non-PCV serotype-
associated disease is imperative to inform future PCV
formulations. Awareness of pneumococcal disease
by healthcare professionals remains of paramount
importance.
NOTE
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
hyg).
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